Product portfolio renewal is one of the main growth drivers in Aché’s strategy. The creation of the Innovation unit further spurs our advance. In 2015 we launched 25 new products serving different medical specialties, including oncology, gastroenterology, women’s health, the central nervous system, cardiology and respiratory health among other areas.
Once structured and presented by the New Products Development Area in a process involving our business units and diverse areas of the company, projects are approved at the Innovation Committees before going to the Project management Office (PMO), which applies disciplined and structured methodology as well as relevant best practices that have made Aché into a company that stands out in product launches.
142 new products launched in the last five years
|Aché product launches|
In line with the globalization strategy outlined in the Strategic Plan, in 2015 Diosmin enters the Ecuadorian market.
Aché product portfolio composition
Our portfolio contains prescription medicine, OTC drugs, generics, dermatologics and dermocosmetics, nutraceuticals and probiotics, covering over 23 medical specialties and serving 139 therapeutic classes.